Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 8/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | SCN4A | P35499 | 4/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29887044 | 0.84 | GPR119 (0.43) | SCN3ASCN9ASCN5AHSP90AA1HSP90AB1 | |
| SCHEMBL17377613 | 0.80 | GPR119 (0.38) | SCN3ASCN9AHSP90AA1HSP90AB1GPR119 | |
| SCHEMBL14212793 | 0.80 | SCN3A (0.42) | SCN3ASCN9ASCN4ASCN5AHSP90AA1 | |
| SCHEMBL3022556 | 0.77 | SCN3A (0.41) | SCN3ASCN9ASCN4ASCN5AHSP90AA1 | |
| SCHEMBL21449421 | 0.75 | GPR119 (0.42) | SCN3ASCN9ASCN5AGPR119L3MBTL1 | |
| SCHEMBL12764747 | 0.75 | SCN3A (0.40) | SCN3ASCN9ASCN4ASCN5AHSP90AA1 | |
| SCHEMBL1126152 | 0.74 | SCN3A (0.39) | SCN3ASCN9ASCN4ASCN5AHSP90AA1 | |
| SCHEMBL23165019 | 0.73 | SCN3A (0.41) | SCN3ASCN9ASCN4ASCN5AHSP90AA1 | |
| SCHEMBL1518152 | 0.73 | SCN3A (0.39) | SCN3ASCN9ASCN4ASCN5AHSP90AA1 | |
| SCHEMBL12821621 | 0.73 | SCN3A (0.41) | SCN3ASCN9ASCN4ASCN5AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | ESKER THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | TYK2, JAK1, PDXK | SCN3A 3741/4885SCN9A 3010/4885SCN4A 4114/4885 |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | SCN3A 4129/4885SCN9A 4179/4885SCN4A 4574/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | SCN3A 4002/4885SCN9A 4013/4885SCN4A 4111/4885 |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | SCN3A 4129/4885SCN9A 4179/4885SCN4A 4574/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | SCN3A 2468/4885SCN9A 3675/4885SCN4A 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.